Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience

Bhatlapenumarthi, Vineel; Patwari, Anannya; Harb, Antoine

doi:10.1007/s00432-021-03610-w

Cited by 18 publications

(23 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Table 1 summarizes the available data on the timing of ICI resumption after a first irAE, showing that it ranges from a median of 14 days [ 29 ] to 60 weeks [ 30 ]. It also bears mentioning that some studies have not reported this variable but provided a clear minimal time lapse between ICI discontinuation and ICI resumption.…”

Section: When Time and Words Matter To Define The Resumption Of Ici(s...mentioning

confidence: 99%

“…Even though all of these studies are retrospective, they all present a Newcastle Ottawa Scale score ≥6, reflecting high quality. Most are multicentric, except for four studies [ 30 , 39 , 40 , 42 ]. Only four studies contained data of more than 100 patients with ICI resumption [ 21 , 32 , 33 , 38 ].…”

Section: Safety Of Resumption Of Ici After a First Iraementioning

confidence: 99%

“…Aside from heterogeneity in the timing range of ICI resumption ( Table 1 ), the studies were heterogeneous in terms of malignancy type and ICI regimen. Moreover, different studies assessed the safety of ICI resumption through the perspective of cancer type (i.e., renal cell carcinoma, melanoma, non-small-cell lung cancer) [ 31 , 34 , 37 , 39 , 40 , 41 , 42 , 44 , 46 ], irAE type (i.e., acute kidney injury, immune-mediated diarrhea and colitis (IMDC)) [ 32 , 35 , 38 ] or both [ 21 , 29 , 30 , 33 , 36 , 43 ].…”

Section: Safety Of Resumption Of Ici After a First Iraementioning

confidence: 99%

See 2 more Smart Citations

Safety of Immune Checkpoint Inhibitor Resumption after Interruption for Immune-Related Adverse Events, a Narrative Review

Allouchery

Beuvon

Pérault‐Pochat

et al. 2022

Cancers

View full text Add to dashboard Cite

Immune checkpoint inhibitors (ICIs) have become the standard of care for several types of cancer due to their superiority in terms of survival benefits in first- and second-line treatments compared to conventional therapies, and they present a better safety profile (lower absolute number of grade 1–5 adverse events), especially if used in monotherapy. However, the pattern of ICI-related adverse events is totally different, as they are characterized by the development of specific immune-related adverse events (irAEs) that are unique in terms of the organs involved, onset patterns, and severity. The decision to resume ICI treatment after its interruption due to irAEs is challenged by the need for tumor control versus the risk of occurrence of the same or different irAEs. Studies that specifically assess this point remain scarce, heterogenous and mostly based on small samples of patients or focused only on the recurrence rate of the same irAE after ICI resumption. Moreover, patients with grade ≥3 irAEs were excluded from many of these studies. Herein, we provide a narrative review on the field of safety of ICI resumption after interruption due to irAE(s).

show abstract

Section: When Time and Words Matter To Define The Resumption Of Ici(s...mentioning

confidence: 99%

Section: Safety Of Resumption Of Ici After a First Iraementioning

confidence: 99%

Section: Safety Of Resumption Of Ici After a First Iraementioning

confidence: 99%

See 1 more Smart Citation

Safety of Immune Checkpoint Inhibitor Resumption after Interruption for Immune-Related Adverse Events, a Narrative Review

Allouchery

Beuvon

Pérault‐Pochat

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Reintroducing the same anti-PD1 treatment can also result in some of the patients experiencing the same cutaneous adverse reactions, or some even new ones. Recurrence of the side effects may occur with decreased frequency (37)(38)(39).…”

Section: Discussionmentioning

confidence: 99%

Cutaneous adverse reactions in a lung cancer patient treated with pembrolizumab: A case report

et al. 2021

View full text Add to dashboard Cite

“…Likewise, a higher risk for mild irAEs and discontinuation of ICIs have been observed in patients with underlying autoimmune diseases, whereas the risk and incidence of moderate to severe irAEs are not observed to be higher ( Reck et al, 2021 ). No impact on ICIs efficacy and tumor clearance has been reported in patients on glucocorticoids or other immunosuppressive therapeutics, and objective response rates and overall survival are reported to be similar in patients with and without autoimmune diseases ( Reck et al, 2021 ), although additional studies of efficiency of ICIs efficacy in this population are warranted ( Bhatlapenumarthi et al, 2021 ).…”

Section: Introductionmentioning

confidence: 99%

Bridging the Gap: Connecting the Mechanisms of Immune-Related Adverse Events and Autoimmunity Through PD-1

Mor

Strazza

2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

The emergence of anti–cytotoxic T-lymphocyte antigen 4 (anti-CTLA-4), anti–programmed cell death 1 ligand (anti–PD-1), and anti–PD-L1 antibodies as immune checkpoint inhibitors (ICIs) revolutionized the treatment of numerous types of tumors. These antibodies, both alone and in combination, provide great clinical efficacy as evidenced by tumor regression and increased overall patients’ survival. However, with this success comes multiple challenges. First, while patients who respond to ICIs have outstanding outcomes, there remains a large proportion of patients who do not respond at all. This all-or-none response has led to looking downstream of programmed cell death 1 (PD-1) for additional therapeutic targets and for new combination therapies. Second, a majority of patients who receive ICIs go on to develop immune-related adverse events (irAEs) characterized by end-organ inflammation with T-cell infiltrates. The hallmarks of these clinically observed irAEs share many similarities with primary autoimmune diseases. The contribution of PD-1 to peripheral tolerance is a major mechanism for protection against expansion of self-reactive T-cell clones and autoimmune disease. In this review, we aim to bridge the gaps between our cellular and molecular knowledge of PD-1 signaling in T cells, ICI-induced irAEs, and autoimmune diseases. We will highlight shared mechanisms and the potential for new therapeutic strategies.

show abstract

Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience

Cited by 18 publications

References 44 publications

Safety of Immune Checkpoint Inhibitor Resumption after Interruption for Immune-Related Adverse Events, a Narrative Review

Safety of Immune Checkpoint Inhibitor Resumption after Interruption for Immune-Related Adverse Events, a Narrative Review

Cutaneous adverse reactions in a lung cancer patient treated with pembrolizumab: A case report

Bridging the Gap: Connecting the Mechanisms of Immune-Related Adverse Events and Autoimmunity Through PD-1

Contact Info

Product

Resources

About